Boss, Kristina
Paar, Margret
Waterstradt, Katja
Schnurr, Kerstin
Ickerott, Philipp
Wieneke, Ulrike
Spitthöver, Ralf
Oettl, Karl
Kribben, Andreas
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 18 May 2023
Accepted: 4 September 2023
First Online: 18 September 2023
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local ethics committee of the University of Duisburg-Essen (22-10806-BO). Informed consent was obtained from all the participant.
: All participants gave written informed consent for publication.
: Karl Oettl has received the Albus Award by Grifols SA, Spain and is consultant of Takeda Pharmaceuticals International AG. Margret Paar has received the Albus Award by Grifols SA, Spain. Andreas Kribben has received grants for clinical studies, speaker’s fees, honoraria, and travel expenses from Actelion, Amgen, Amicus, Alexion, Astellas, Bayer, Baxter, Binding Site, Bristol Myers, Chiesi, CytoSorbents, Fresenius, GlaxoSmithKline, Hexal, Janssen, Kyowa Kirin, MSD, Novartis, Otsuka, Peripal, Pfizer, Roche, Sanofi, Shire, Teva, and Vifor Fresenius Medical. All other authors declare no conflict of interests.